Our Guest: #2 - Spiro Rombotis, CEO at Cyclacel Pharmaceuticals

What you'll get out of this episode:

• Rombotis's background and an overview of Cyclacel
• Which part of the cell cycle they're targeting?
• What their leading candidates are, and the current clinical trial statuses of each.
• What makes their CDK inhibitor strategy unique compared to other biopharmaceutical companies?
• Their PLK1 program
• Near-term milestones and what's next?

Our sponsors for this episode are Sage Growth Partners

Sage Growth Partners accelerates commercial success for healthcare organizations through a singular focus on growth. The company helps its clients thrive amid the complexities of a rapidly changing marketplace with deep domain expertise and an integrated application of research, strategy, and marketing. For more information, please go to www.sage-growth.com & follow Sage Growth Partners on social media - @sagegrowthpartners